-+ 0.00%
-+ 0.00%
-+ 0.00%

Definium doses first patient in Phase 3 Ascend trial of DT120 ODT for MDD

PUBT·05/12/2026 11:02:20
Listen to the news
Definium doses first patient in Phase 3 Ascend trial of DT120 ODT for MDD
  • Definium Therapeutics started dosing patients in Ascend, second Phase 3 pivotal study of DT120 orally disintegrating tablet for major depressive disorder.
  • Trial targets 175 participants in US, compares DT120 versus placebo, with main readout focused on whether treatment reduces depression symptoms versus placebo.
  • Topline results from 12-week blinded portion are expected in 2027, meaning no results from Ascend have been presented yet.
  • Program builds on earlier mid-stage study in generalized anxiety disorder that suggested DT120 could improve depression symptoms.
  • Definium also expects topline results from its first Phase 3 MDD study, Emerge, in late 2Q 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605120700BIZWIRE_USPR_____20260512_BW064160) on May 12, 2026, and is solely responsible for the information contained therein.